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Palbociclib has no clinically relevant effect on the QTc interval
in patients with advanced breast cancer
Chandrasekar Durairaja, Ana Ruiz-Garciaa, Eric R. Gauthierb, Xin Huanga,
Dongrui R. Lua, Justin T. Hoffmana, Richard S. Finnd, Anil A. Joye, Johannes Ettlf,
Hope S. Rugoc, Jenny Zhenga, Keith D. Wilnera and Diane D. Wanga
The aim of this study was to assess the potential effects of
palbociclib in combination with letrozole on QTc. PALOMA-2,
a phase 3, randomized, double-blind, placebo-controlled
trial, compared palbociclib plus letrozole with placebo plus
letrozole in postmenopausal women with estrogen
receptor-positive, human epidermal growth factor receptor
2-negative advanced breast cancer. The study included a
QTc evaluation substudy carried out as a definitive QT
interval prolongation assessment for palbociclib. Time-
matched triplicate ECGs were performed at 0, 2, 4, 6, and 8 h
at baseline (Day 0) and on Cycle 1 Day 14. Additional ECGs
were collected from all patients for safety monitoring. The
QT interval was corrected for heart rate using Fridericia’s
correction (QTcF), Bazett’s correction (QTcB), and a study-
specific correction factor (QTcS). In total, 666 patients were
randomized 2 : 1 to palbociclib plus letrozole or placebo
plus letrozole. Of these, 125 patients were enrolled in the
QTc evaluation substudy. No patients in the palbociclib plus
letrozole arm of the substudy (N= 77) had a maximum
postbaseline QTcS or QTcF value of Z 480ms, or a
maximum increase from clock time-matched baseline for
QTcS or QTcF values of Z 60ms. The upper bounds of the
one-sided 95% confidence interval for the mean change
from time-matched baseline for QTcS, QTcF, and QTcB at all
time points and at steady-state Cmax following repeated
administration of 125mg palbociclib were less than 10ms.
Palbociclib, when administered with letrozole at the
recommended therapeutic dosing regimen, did not prolong
the QT interval to a clinically relevant extent. Anti-Cancer
Drugs 29:271–280 Copyright © 2018 The Author(s).
Published by Wolters Kluwer Health, Inc.
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Introduction
Certain drugs are known to cause a delay in cardiac repolar-
ization, which can be measured as prolongation of the QT
interval on an ECG [1,2]. Delay in cardiac repolarization is
considered undesirable because it increases the risk of cardiac
arrhythmias, most notably torsades de pointes (TdP), which can
lead to sudden cardiac death [3]. Drugs in clinical develop-
ment are recommended by the International Conference on
Harmonization (ICH) guidance to be evaluated rigorously in a
well-controlled, thorough QT/corrected QT (QTc) clinical
study (i.e. TQT study) for their potential to prolong the QT
interval/QTc to evaluate the risk–benefit ratio of cardiac
arrhythmias during prolonged use [4].
A TQT study is typically carried out in healthy indivi-
duals and includes a placebo control, a positive control,
and at least one dose level higher than those adminis-
tered clinically to achieve supratherapeutic concentra-
tions. However, the potential toxicity profiles associated
with anticancer drugs often preclude their administration
to healthy individuals, thus presenting unique challenges
in the implementation of a TQT study for most antic-
ancer drugs. When evaluating a drug effect on QTc
prolongation in patients, it is often not feasible to include
a placebo control to rule out the nondrug effects or a
positive control to establish the sensitivity of the study
[5]. Furthermore, the potential toxicity of anticancer
drugs may preclude evaluating their effects on QTc
prolongation at a supratherapeutic dose. However, in
cases where a dedicated TQT study in healthy indivi-
duals cannot be carried out, evaluation of the drug effect
on QTc in the target patient population with a reduced
study design at the therapeutic dose accompanied by
exposure–response analysis of the concentration–QTc
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data can be considered an alternative approach to assess
the potential drug effect on cardiac repolarization [6].
Palbociclib is a highly selective oral inhibitor of cyclin-
dependent kinase 4/6 (CDK4/6) [7]. Cyclin D1 and
CDK4/6 are downstream of signaling pathways that lead
to cellular proliferation [8]. In vitro, palbociclib reduced
cellular proliferation of estrogen receptor-positive breast
cancer cell lines by blocking progression of the cell from
G1 into the S phase of the cell cycle [9]. Palbociclib is
currently approved for the treatment of patients with
hormone receptor-positive, human epidermal growth
factor receptor 2-negative advanced or metastatic breast
cancer in combination with an aromatase inhibitor as
initial endocrine-based therapy in postmenopausal
women or fulvestrant in women with disease progression
following endocrine therapy [10,11] and is under clinical
investigation in numerous other oncologic settings [12].
The effects of palbociclib on cardiac conduction were
characterized in an in-vitro human Ether-a-Go-Go assay
(hERG) and in telemetrized dog studies. The results
of these assessments indicated a potential for QT pro-
longation at unbound palbociclib concentrations of Z
four-fold the unbound steady-state Cmax associated with
the therapeutic dose of 125 mg once daily [13]. During
early clinical development in phase 1 and 2 trials, the
effect of palbociclib on QTc prolongation was investi-
gated [14]. An exposure–response analysis was carried
out to evaluate the relationship between palbociclib
concentrations and QTc changes using ECG data and
blood samples for palbociclib plasma exposure con-
centrations obtained immediately after each ECG
assessment. These blood samples were collected from
184 patients with advanced cancer who were receiving
palbociclib doses ranging from 25 to 225 mg once daily in
three early clinical studies. The predicted upper bound
of the one-sided 95% confidence interval (CI) for the
increase in QTc at the mean maximal steady-state pal-
bociclib concentrations at 125 mg once daily was less than
10ms, indicating a lack of clinically relevant effect on
QTc prolongation [14]. However, time-matched baseline
ECGs were not collected in those studies and the ECG
data were not assessed by a central laboratory. Hence, a
more rigorous evaluation of the potential effect of pal-
bociclib on QTc was carried out in a well-controlled
substudy in the target population of patients with
advanced breast cancer (ABC) at 125 mg once daily.
PALOMA-2 is a phase 3, international, multicenter, rando-
mized, double-blind, placebo-controlled trial designed to
demonstrate that the combination of palbociclib with letro-
zole is superior to placebo plus letrozole in prolonging
progression-free survival in postmenopausal women with
estrogen receptor-positive/human epidermal growth factor
receptor 2-negative ABC who had not received any previous
systemic therapy for their advanced/metastatic disease [15].
Because of the aforementioned challenges in carrying out a
typical TQT study with oncology drugs and in accordance
with the ICH E14 guidelines on the alternative approaches
to investigate the potential for QTc prolongation [4], this
study included a QTc evaluation substudy where intensive
ECG and pharmacokinetic (PK) data were collected to
characterize the effect of palbociclib on QTc.
Patients and methods
Study design, patients, and treatments
Full details of the PALOMA-2 study design, patient popu-
lation, key exclusion criteria, and study assessments have been
published previously [15] (see Supplementary Section 1.1 in
Supplemental digital content 1, http://links.lww.com/ACD/A235,
which shows additional details on the study population and
key exclusion criteria). Briefly, 666 patients were randomized
2 : 1 to the palbociclib plus letrozole arm or to the placebo plus
letrozole arm. A subset of investigational sites in PALOMA-2
participated in the QTc evaluation substudy.
Patients assigned to the palbociclib plus letrozole arm
received palbociclib 125mg orally once daily from Day 1 to
Day 21 of every 28-day cycle, followed by 7 days off treat-
ment in combination with letrozole 2.5mg orally once daily
continuously. Those in the placebo plus letrozole arm
received placebo orally from Day 1 to Day 21 of every
28-day cycle, followed by 7 days off treatment in combina-
tion with letrozole 2.5mg orally once daily continuously.
PALOMA-2 was conducted in compliance with the
ethical principles of Declaration of Helsinki and ICH
Good Clinical Practice guidelines. The final protocol, any
amendments, and informed consent documentation were
approved by the institutional review board(s) and/or the
independent ethics committee(s) at each investigational
center participating in the study. All patients provided
written informed consent.
ECG assessments
A centralized ECG collection system provided by
Biomedical Systems (St Louis, Missouri, USA) was utilized
in this study. Standardized ECG machines (Mortara ELI
150c; Mortara Instrument Inc., Milwaukee, Wisconsin,
USA) with consistent software were supplied by Biomedical
Systems to the study sites. All ECGs were performed using
a 12-lead (with a 10-s rhythm strip) tracing.
For intensive ECG assessment, triplicate (recorded
∼2min apart, but within 10min) ECGs were obtained at 0,
2, 4, 6, and 8 h on the day preceding the start of blinded
study treatment (Day 0, baseline) from the patients partici-
pating in the QTc evaluation substudy. On Cycle 1 Day 14
(C1D14±2 days), when palbociclib concentrations would
have achieved steady state, triplicate ECGs were collected
at time points clock time-matched to the corresponding
baseline ECG assessments on Day 0 (±35min). Dosing of
blinded study treatments (palbociclib/placebo) with letro-
zole was to occur following the collection of time ‘0’ tripli-
cate ECGs and the associated PK sample on C1D14.
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To assess the safety of palbociclib, triplicate ECGs were
obtained at 0 h (predose) on Day 1 of Cycle 1 and Day 14
of Cycles 1 and 2, then on Day 1 of Cycles 4, 7, and 10
from all patients in the study. ECGs beyond Cycle 10
were performed as indicated clinically.
All ECGs had to be obtained after a fast of at least 1 h and
when scheduled at the same time as PK blood draws, the
ECGs had to be performed immediately before the
respective sampling times. All ECG tracings were sent to
a central laboratory for blinded manual adjudication (e.g.
computer-assisted, with manual over-read when appro-
priate), and the resulting measurements were used as the
data inputs for the planned QTc evaluations. The ECG
measurements included the PR interval, the QT interval,
the RR interval, and the QRS complex.
Pharmacokinetic assessments
Blood samples were collected from all participating patients in
the QTc evaluation substudy for PK assessments of palbo-
ciclib on C1D14 at predose (0 h) and at 2, 4, 6, and 8 h
postdose. All PK samples were to be collected immediately
after triplicate ECGs were obtained. Plasma concentrations of
palbociclib were determined using high-performance liquid
chromatography tandem mass spectrometry as described
previously [16]. The linearity of the calibration curve for
palbociclib was in the range of 1–250 ng/ml and the lower
limit of quantification for the palbociclib assay was 1.00 ng/ml.
Statistical analysis
Sample size determination
Sample size determination for the QTc evaluation substudy
was based on a noninferiority hypothesis testing framework.
To establish noninferiority between postbaseline and base-
line (Day 0) (ΔQTc) at all five QTc time points on C1D14
with 90% power, ∼60 patients were to be included for QTc
evaluation to ensure 40 evaluable patients in the palbociclib
plus letrozole treatment arm (2 : 1 randomization) of the QTc
evaluation substudy. The test was based on a one-sided t-
test for the pairedΔQTc mean difference with a significance
level of 0.05. The difference in means betweenΔQTc under
the alternative hypothesis was 10ms, assuming a non-
inferiority margin of 20ms and the standard deviation of the
paired differences equal to 16ms on the basis of QTc data
from PALOMA-1 [17]. If the upper bounds of one-sided
95% CI of ΔQTc for all five QTc postbaseline time points
were less than 20ms, the postbaseline QTc’s were to be
considered noninferior to baseline, and the effect of the
treatment of palbociclib plus letrozole on QTc was to be
deemed not clinically relevant.
Pharmacokinetic analysis
For patients in the QTc evaluation substudy, PK parameters
[maximum observed concentration (Cmax), time of Cmax (tmax),
area under the curve from 0 to 24 h (AUC0–24), and oral
clearance (CL/F)] were calculated from the PK samples col-
lected on C1D14 using electronic noncompartmental analysis,
version 2.2.4 (Pfizer Inc., Groton, Connecticut, USA). The
predose plasma concentration was used as both the 0 and 24 h
values for the calculation of AUC0–24. All PK parameters
presented here were calculated using PK samples that ful-
filled the dose-compliance criteria (see Supplementary
Section 1.2 in Supplemental digital content 1, http://links.lww.
com/ACD/A235, describing dose-compliance criteria).
ECG summaries
In this study, separate analyses were carried out to sum-
marize the ECG data for patients in the QTc evaluation
substudy (QTc evaluation population) and all treated
patients with ECG data (safety-analysis population; see
Supplementary Section 1.3 in Supplemental digital content 1,
http://links.lww.com/ACD/A235, which defines the analysis
populations). The average (arithmetic mean) of triplicate
ECG measurements at each time point for each patient was
used for all summary statistics, data presentations, and ana-
lyses. If one or two of the triplicate ECGmeasurements were
missing, the average of the remaining two measurements or
the single measurement was used in the analysis. To
diminish the dependence of the QT interval on heart rate,
three correction methods were evaluated including the
Bazett’s [QT interval corrected for heart rate using Bazett’s
formula (QTcB=QT/RR0.5)], Fridericia’s (QTcF=QT/
RR0.33), and a study-specific correction method (QTcS=
QT/RRS, where S is the slope of linear regression between
unaveraged singlet values of the natural log of QT and RR
intervals). QTcF was chosen prospectively as the primary
endpoint for QTc analysis.
In the QTc evaluation population, for each patient at
each time point (0, 2, 4, 6, and 8 h), the ΔQTc was cal-
culated by subtraction of the time-matched baseline
value (collected on Day 0) at a particular time point from
the appropriately matched postbaseline value (collected
on C1D14). Summary statistics of maximum postbaseline
QTc (QTcF, QTcB, and QTcS) values and maximum
change from baseline values for ECG parameters (QTcF,
QTcB, QTcS, PR interval, and QRS complex) were
calculated separately for each treatment arm. The cate-
gories used for the frequency distribution were <450, 450
to <480, 480 to <500, and ≥ 500 ms for QTc; <30, 30 to
<60, and ≥ 60 ms for ΔQTc; ≥ 50% PR interval changes
from baseline if the absolute baseline value was <200 ms
and ≥ 25% PR interval changes from baseline if the
absolute baseline value was ≥ 200 ms; ≥ 50% QRS com-
plex changes from baseline if the absolute baseline value
was less than 100 ms; and Z 25% QRS complex changes
from baseline if the absolute baseline value was Z
100 ms. A random-effects model with the nominal time
point (including visit and treatment group) as a fixed
effect and the patient as a random effect was used to
estimate the mean change in ECG data from clock time-
matched baseline at each postbaseline nominal time
point. For each ECG parameter, the point estimates of
the least squares (LS) mean changes from baseline at all
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five time points and their two-sided 90% CI were sum-
marized, and the resulting data for QTc parameters were
tabulated and displayed graphically.
In the safety-analysis population, the most recent triplicate
ECG assessment collected before the first dose of study
medication was defined as the baseline. For each patient at
each time point, the ΔQTc was calculated by subtraction of
the baseline value from the postbaseline values. The same
categories used for the QTc evaluation population were
used to summarize the ECG data in this population.
Exposure–response analysis
The dataset used for assessing the concentration–QTc/
RR relationships included the arithmetic mean of tripli-
cate ECG measurements and the corresponding palbo-
ciclib concentrations from PK samples collected no more
than 1 h apart at each time point in the QTc evaluation
population. For baseline ECG measurements collected
on Day 0, the corresponding palbociclib concentrations
were set to 0 and included in the analysis. Observations
with missing ECG or covariate data were not imputed.
A stepwise approach was used to assess the relationship
between palbociclib concentrations and QTc. Because the
QT interval is dependent on heart rate, the effect of palbo-
ciclib on the RR interval was evaluated in the QTc evaluation
population before correcting the QT interval. If no correlation
existed between the palbociclib concentration and the RR
interval, a two-stage analysis was to be carried out where the
appropriate correction method (QTcB, QTcF, or QTcS) that
best removes the correlation between QT and RR intervals
was first determined, followed by characterization of the
relationship between the palbociclib concentration and the
QTc. If a correlation existed between the palbociclib con-
centration and the RR interval, the relationship between drug
concentration and the QT interval was to be characterized by
a one-stage approach where the effect of drug on both RR
and QT intervals was ascertained simultaneously.
A linear mixed-effects model was used to assess the rela-
tionships of the RR interval and QTc with the palbociclib
concentration. The mean absolute values of triplicate RR
and QTc intervals, rather than change from baseline, were
used in the analyses. Nominal time was included as a
factor variable on the intercept to remove the potential
effect of circadian rhythm on the RR interval and QTc as
shown in the following model equations:
RRij ¼ y1þ y2þ y3þ y4þ y5þ Zð1Þi
þ y6þ Zð2Þi
 
Concij þ eij;
Eq. (1)
QTcij ¼ y1þ y2þ y3þ y4þ y5
þ Zð1Þi þ y6þ Zð2Þi
 
Concij þ eij ;
Eq. (2)
where j indexes the measurement time for the ith patient.
The intercept parameters θ1, θ2, θ3, θ4, and θ5 represent the
mean RR interval or QTc in the absence of drug (Conc= 0
for baseline data) at nominal collection times 0, 2, 4, 6, and
8 h, respectively; θ6 represents the population mean slope;
ηi
(1) and ηi
(2) represent patient-specific random effects,
which were assumed to be normally distributed with mean
0 and variance–covariance matrix Ω and εij represents the
residual random variable with mean 0 and variance σ2.
All model developments, diagnostics including graphical
analysis, preprocessing and postprocessing of data were
performed using R (version 3.2.2; R Foundation for
Statistical Computing, Vienna, Austria). The adequacy of
the models developed was assessed by generating diag-
nostic and goodness-of-fit plots. A visual predictive check
(VPC) for the final model was generated to evaluate
whether the model provided an accurate description of
the data (see Supplementary Section 1.4 in Supplemental
digital content 1, http://links.lww.com/ACD/A235, showing
the model diagnostics for exposure–response analysis).
Results
Patient disposition and demographics
A total of 666 patients were randomized in a 2 : 1 ratio to
palbociclib plus letrozole (444 patients) or placebo plus
letrozole (222 patients). The baseline demographic
characteristics were comparable between the treatment
groups (Table 1). The mean age of the participants was
62 years (range: 30–89 years) in the palbociclib plus
letrozole group and 61 years (range: 28–88 years) in the
placebo plus letrozole group. For safety analysis, ECGs
were to be obtained from all patients during the study.
The number of patients in the safety-analysis population
who had both baseline and postbaseline ECGs were 443
in the palbociclib plus letrozole arm and 220 in the pla-
cebo plus letrozole arm.
Due to the differences in the patient recruitment rate at
various sites participating in the QTc evaluation substudy
and the need to replace the patients who did not complete
all PK collections and matched ECG assessments at both
baseline and C1D14, more patients were enrolled than the
initially planned 60 patients. A total of 125 patients were
enrolled in the QTc evaluation substudy. Of these 125
patients, 77 were randomized to the palbociclib plus
letrozole arm (76 provided postbaseline ECG data) and 48
were randomized to the placebo plus letrozole arm. The
minimum number of clock time-matched baseline and
C1D14 ECG pairs available at each time point in the
palbociclib plus letrozole arm and placebo plus letrozole
arm were 70 and 46, respectively. All 76 patients in the
palbociclib plus letrozole arm who provided postbaseline
assessments received daily 125mg doses continuously up
to the QTc assessment day. Baseline demographic char-
acteristics were generally similar between the palbociclib
plus letrozole group in the safety-analysis population and
the QTc evaluation population, indicating that the QTc
evaluation population is representative of the safety-
analysis population (Table 1).
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Plasma pharmacokinetics of palbociclib
Of the 77 patients randomized to the palbociclib plus
letrozole arm in the QTc evaluation substudy, a total of 70
patients provided palbociclib concentration data and there
were a minimum of 41 patients contributing to each of the
PK parameters. Following oral doses of palbociclib 125mg
once daily with letrozole 2.5mg once daily, palbociclib
steady-state geometric mean AUC0–24 and Cmax were
1992 ngh/ml and 110.4 ng/ml, respectively. The palbociclib
geometric mean apparent CL/F at steady state was 62.71L/h
and the median tmax was 5.83 h (range: 1.87–8.18 h). The
arithmetic mean and the median Cmax values (116.6 and
117 ng/ml, respectively) from this analysis were used to
predict the mean drug-induced changes in QTc.
ECG analysis results
ECG substudy analysis (QTc evaluation population)
QTcS provided the best correction for the effect of heart
rate on the QT interval for the QTc evaluation population,
followed by QTcF and QTcB (see Supplementary Section
2.1 in Supplemental digital content 2, http://links.lww.com/
ACD/A236, and Supplementary Fig. 1 in Supplemental
digital content 3, http://links.lww.com/ACD/A237, which
shows the relationship between QTc vs. RR intervals in
the QTc evaluation population). QTcS, along with QTcF
(the prespecified primary endpoint), were used for QTc
analysis data interpretation and conclusion. The results of
the QTcB analysis were included for completeness.
The results from the random-effects models used to
estimate the mean change in ECG parameters from clock
time-matched baseline at each postbaseline nominal time
point are summarized in Table 2. The LS mean changes
from time-matched baseline across ECG assessment time
points are shown in Fig. 1. For treatment with palbociclib
plus letrozole, LS mean changes from time-matched
baseline for QTcS and QTcF ranged from 0.80 to
4.57 ms on C1D14, with the largest value reported at 6 h
postdose for both parameters. This is consistent with the
observed median tmax for palbociclib (5.83 h), indicating
that there is no delay in the effect of palbociclib on the
QTc, and thus there does not appear to be any evidence
for hysteresis in the data. The upper bounds of the one-
sided 95% CI for the LS mean change from time-
matched baseline for QTcS and QTcF were less than
10 ms at all C1D14 time points (Fig. 1). For treatment
with placebo plus letrozole, the LS mean changes from
time-matched baseline in QTcS and QTcF ranged from
0.71 to 3.14 ms on C1D14, with the largest value reported
at 8 h for QTcS and at 0 h for QTcF. The upper bounds
of the one-sided 95% CIs for the LS mean change from
time-matched baseline for QTcS and QTcF were less
than 10 ms at all C1D14 time points monitored.
Categorical summaries of maximum postbaseline and
maximum change from clock time-matched baseline
ECG parameters for the QTc evaluation population are
summarized in Table 3 to describe population outliers. In
the QTc evaluation population, no patients in the pal-
bociclib plus letrozole arm had a maximum postbaseline
QTcS or QTcF value of Z 480 ms or a maximum
increase from clock time-matched baseline for QTcS or
QTcF values of Z 60 ms. In the placebo plus letrozole
arm, two (4.2%) patients had a QTcS value between 480
Table 1 Baseline demographic characteristics of the safety-analysis population and the QTc evaluation population
Demographics Palbociclib + Letrozole Placebo+ Letrozole Total
Safety-analysis population
Number of patients 444 222 666
Age (years)
Mean (SD) 61.7 (10.6) 60.6 (11.2) 61.3 (10.8)
Median (range) 62.0 (30–89) 61.0 (28–88) 62.0 (28–89)
Weight (kg)
Mean (SD) 70.7 (16.7) 70.7 (17.0) 70.7 (16.8)
Median (range) 68.0 (33.0–156.8) 66.8 (35.0–124.8) 67.5 (33.0–156.8)
Race [n (%)]
White 344 (77.5) 172 (77.5) 516 (77.5)
Black 8 (1.8) 3 (1.4) 11 (1.7)
Asian 65 (14.6) 30 (13.5) 95 (14.3)
Othera 27 (6.1) 17 (7.7) 44 (6.6)
QTc evaluation population
Number of patients 77 48 125
Age (years)
Mean (SD) 61.2 (10.6) 61.2 (7.83) 61.2 (9.62)
Median (range) 62.0 (36–86) 62.0 (42–77) 62.0 (36–86)
Weight (kg)
Mean (SD) 75.2 (20.2) 68.1 (17.4) 72.5 (19.4)
Median (range) 72.3 (48.1–157) 63.6 (34.5–112) 66.7 (34.5–157)
Race [n (%)]
White 63 (81.8) 39 (81.2) 102 (81.6)
Black 2 (2.6) 0 2 (1.6)
Asian 7 (9.1) 6 (12.5) 13 (10.4)
Othera 5 (6.5) 3 (6.2) 8 (6.4)
aOther includes unreported and missing patients.
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and less than 500 ms, one (2.1%) patient had a QTcF
value between 480 and less than 500 ms, and no patient
had a maximum postbaseline QTcS or QTcF value of Z
500 ms. No patient had a maximum increase from time-
matched baseline in QTcS or QTcF values of Z 60 ms
in the placebo plus letrozole arm.
As shown in Tables 2 and 3, there were no clinically
meaningful changes from clock time-matched baseline
values for the PR interval, the QRS complex, or the RR
interval in the QTc evaluation population on C1D14.
ECG analysis (safety-analysis population)
Results from the analysis of safety-analysis population indi-
cate that there was no evidence of clinically significant
effects of palbociclib plus letrozole on QTc, the PR interval,
or the QRS complex (see Supplementary Section 2.2 in
Supplemental digital content 2, http://links.lww.com/ACD/
A236, showing ECG analysis for the safety-analysis popula-
tion; Supplementary Fig. 2 in Supplemental digital content 3,
http://links.lww.com/ACD/A237, illustrating the relationship
between QTc vs. RR intervals in the safety-analysis popu-
lation; and Supplementary Table 1 in Supplemental digital
content 4, http://links.lww.com/ACD/A238, showing categorical
summary of the maximum postbaseline and maximum
increase from the baseline of ECG parameters for the safety-
analysis population). Further, there was no trend in the
mean changes from baseline across ECG assessment days
for the treatment duration in either treatment arm for QTcS
or QTcF (see Supplementary Fig. 3 in Supplemental digital
content 3, http://links.lww.com/ACD/A237, showing changes
from baseline in QTcS and QTcF over time in the palbo-
ciclib plus letrozole arm in the safety-analysis population).
Exposure–response analysis of ECG data
Data for the concentration–QTc/RR population included
a total of 320 matched PK-ECG pairs from 70 patients in
the palbociclib plus letrozole treatment arm. The average
age and baseline body weight of patients in the analysis
dataset providing matched PK-ECG pairs was 61.2 years
(range: 36–86 years) and 75.2 kg (range: 48.1–157 kg),
respectively. The average QT interval, RR interval,
QTcF, and QTcS were in the range of 381–387, 795–824,
412–414, and 413–415ms, respectively, across the nom-
inal time points at baseline.
Table 2 Time-matched change from baseline of ECG parameters by time point on Cycle 1 Day 14 for the QTc evaluation population
Palbociclib + Letrozole Placebo+Letrozole
Planned time
postdose n
LS mean (SE) change from
baseline
90% CI of LS mean change
from baseline n
LS mean (SE) change from
baseline
90% CI of LS mean change
from baseline
QTcS (ms)
0 h 76 0.80 (1.50) −1.67–3.26 46 2.95 (1.91) −0.19–6.10
2 h 71 3.32 (1.54) 0.79–5.85 47 1.65 (1.90) −1.48–4.78
4 h 71 2.76 (1.54) 0.23–5.30 47 1.74 (1.90) −1.39–4.87
6 h 71 4.49 (1.54) 1.96–7.02 47 0.72 (1.90) −2.41–3.85
8 h 70 0.94 (1.54) −1.60–3.48 47 3.14 (1.90) 0.01–6.27
QTcF (ms)
0 h 76 1.10 (1.51) −1.39–3.58 46 3.06 (1.92) −0.11–6.23
2 h 71 3.68 (1.55) 1.12–6.23 47 1.73 (1.91) −1.43–4.88
4 h 71 2.86 (1.55) 0.31–5.41 47 1.54 (1.91) −1.62–4.70
6 h 71 4.57 (1.55) 2.01–7.12 47 0.71 (1.91) −2.44–3.87
8 h 70 1.21 (1.55) −1.36–3.77 47 2.84 (1.91) −0.31–6.00
QTcB (ms)
0 h 76 −0.11 (1.65) −2.83–2.61 46 2.78 (2.11) −0.69–6.25
2 h 71 1.46 (1.70) −1.34–4.25 47 0.83 (2.09) −2.63–4.28
4 h 71 2.58 (1.70) −0.22–5.38 47 2.47 (2.09) −0.98–5.92
6 h 71 4.03 (1.70) 1.24–6.83 47 0.53 (2.09) −2.92–3.99
8 h 70 −0.17 (1.70) −2.98–2.64 47 4.14 (2.09) 0.69–7.59
RR interval (ms)
0 h 76 11.8 (10.4) −5.37–28.9 46 4.90 (13.3) −17.0–26.8
2 h 71 25.2 (10.7) 7.58–42.8 47 6.66 (13.2) −15.1–28.4
4 h 71 4.11 (10.7) −13.5–21.7 47 −12.5 (13.2) −34.3–9.22
6 h 71 4.18 (10.7) −13.4–21.8 47 −1.75 (13.2) −23.5–20.0
8 h 70 15.8 (10.7) −1.90–33.5 47 −14.9 (13.2) −36.6–6.89
PR interval (ms)
0 h 76 −0.44 (1.08) −2.23–1.35 45 1.50 (1.40) −0.81–3.81
2 h 71 −1.94 (1.12) −3.78 to −0.10 46 1.30 (1.39) −0.99–3.59
4 h 71 0.26 (1.12) −1.58–2.10 46 0.66 (1.39) −1.63–2.95
6 h 71 1.17 (1.12) −0.67–3.01 46 −1.27 (1.39) −3.57–1.02
8 h 70 1.50 (1.12) −0.35–3.35 46 −0.52 (1.39) −2.81–1.77
QRS complex (ms)
0 h 76 −0.61 (0.741) −1.83–0.61 46 0.13 (0.946) −1.43–1.69
2 h 71 −0.92 (0.762) −2.17–0.34 47 −1.97 (0.941) −3.52 to −0.42
4 h 71 −0.39 (0.762) −1.65–0.86 47 0.43 (0.941) −1.13–1.98
6 h 71 −0.41 (0.762) −1.66–0.85 47 −1.63 (0.941) −3.18 to −0.08
8 h 70 −0.68 (0.765) −1.94–0.58 47 −1.28 (0.941) −2.83–0.28
CI, confidence interval; LS, least square; n, number of patients who had time-matched baseline and postbaseline ECG data at each time point.
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The relationship between the palbociclib concentration and
the RR interval was analyzed using a linear mixed-effects
model with nominal time as a factor variable on the intercept
as shown in Eq. (1). The results indicated that palbociclib had
no effect on the heart rate because the slope (95% CI) esti-
mate cannot be ruled out from 0 [0.0442 (−0.265–0.354)ms/
ng/ml]. Because no correlation was observed between the RR
interval and the drug concentration, fixed correction methods
were used. On the basis of visual inspection of the QTc versus
RR interval plots and the slope values generated for the three
correction methods, QTcS provided the best correction by
decreasing the correlation between QT and RR intervals (see
Supplementary Section 2.3 in Supplemental digital content 2,
http://links.lww.com/ACD/A236, showing the evaluation of
correction factors in exposure–response analysis). Therefore,
QTcS was selected as the primary endpoint for the
exposure–response analysis. Analyses results with QTcF
(prespecified primary endpoint for the QTc substudy) and
QTcB were also included for the purpose of comparison.
The linear mixed-effects model, with random effects on
slope and intercept as well as nominal time as a factor
variable on intercept, was adequate to describe the data
(see Supplementary Table 2 in Supplemental digital
content 4, http://links.lww.com/ACD/A238, showing the
parameter estimates for the final models). The slope
(95% CI) estimates of the final models were 0.0347
(0.00776–0.0616) and 0.0355 (0.00826–0.0628) ms/ng/ml
for QTcS–drug and QTcF–drug concentration, respec-
tively, suggesting a weak correlation between QTc
(QTcS and QTcF) and palbociclib concentration.
Diagnostic plots (not shown) and VPC plots (see
Supplementary Fig. 4 in Supplemental digital content 3,
http://links.lww.com/ACD/A237, which shows the VPC
plot for the final concentration–QTcS model and
concentration–QTcF model) for each model showed
no apparent model misspecifications, indicating that
the models were adequate to describe the observed
data.
Fig. 1
Least-squares mean (90% confidence interval) change from the time-matched baseline in QTc on C1D14 for the QTc evaluation population. (a)
QTcS. (b) QTcF. (c) QTcB.
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Prediction of drug effects on QTc
The final models were used to predict the mean and two-
sided 90% CI change from baseline in QTc at the
observed steady-state mean and median palbociclib Cmax
of 116.6 and 117.0 ng/ml, respectively. As shown in
Table 4, the upper bounds of the two-sided 90% CI
(equivalent to the upper bound of the one-sided 95% CI)
change from baseline in QTc (QTcS and QTcF) at the
mean and median of steady-state palbociclib Cmax were
all less than 10 ms, indicating that palbociclib had no
clinically relevant effect on QTc prolongation at the
recommended therapeutic dosing regimen.
Discussion
The QTc evaluation substudy in PALOMA-2 was carried
out as the definitive study to investigate the potential
effects of palbociclib on cardiac repolarization at the
recommended therapeutic dose of 125 mg once daily in
the target patient population. The results of QTc analysis
as well as concentration–QTc modeling showed that
palbociclib, when coadministered with letrozole, did not
prolong QTc to a clinically relevant extent in patients
with ABC. Findings from the safety assessment in the
phase 3 study and the QTc substudy analysis confirmed
that there were no clinically relevant changes in ECG
parameters. Because letrozole is not associated with
delays in cardiac repolarization, its coadministration with
palbociclib did not confound the results observed in
this study.
Based on the the ICH E14 guideline, the threshold level
of regulatory concern for QTc prolongation is that the
upper bound of the one-sided 95% CI around the largest
time-matched mean effect on QTc is less than 10 ms [4],
whereas the threshold level of less than 20 ms is widely
accepted for oncology drugs. The random-effects analysis
of the QTc data in the QTc evaluation population
showed that the upper bounds of the one-sided 95% CI
for the mean time-matched change from baseline for
QTcF, QTcS, and QTcB were less than 10 ms at all five
time points in the QTc assessment period. In the safety-
analysis population, less than 1% of patients receiving
palbociclib plus letrozole had a postbaseline absolute
Table 3 Categorical summary of maximum postbaseline and maximum increase from baseline of ECG parameters for the QTc evaluation
population
Palbociclib + Letrozole Placebo+ Letrozole
Parameters Criterion N n (%) N n (%)
Maximum QTcS (ms) <450 76 66 (86.8) 48 40 (83.3)
450 to <480 76 10 (13.2) 48 6 (12.5)
480 to <500 76 0 48 2 (4.2)
≥500 76 0 48 0
Maximum QTcF (ms) <450 76 69 (90.8) 48 41 (85.4)
450 to <480 76 7 (9.2) 48 6 (12.5)
480 to <500 76 0 48 1 (2.1)
≥500 76 0 48 0
Maximum QTcB (ms) <450 76 49 (64.5) 48 30 (62.5)
450 to <480 76 26 (34.2) 48 12 (25.0)
480 to <500 76 1 (1.3) 48 5 (10.4)
≥500 76 0 48 1 (2.1)
Maximum QTcS increase from baseline (ms) Change<30 76 72 (94.7) 48 46 (95.8)
30≤ change<60 76 4 (5.3) 48 2 (4.2)
Change≥60 76 0 48 0
Maximum QTcF increase from baseline (ms) Change<30 76 71 (93.4) 48 46 (95.8)
30≤ change<60 76 5 (6.6) 48 2 (4.2)
Change≥60 76 0 48 0
Maximum QTcB increase from baseline (ms) Change<30 76 71 (93.4) 48 44 (91.7)
30≤ change<60 76 5 (6.6) 48 4 (8.3)
Change≥60 76 0 48 0
Maximum PR interval increase from baseline (ms) Change≥25% and baseline≥200 ms 76 0 47 0
Change≥50% and baseline<200 ms 76 0 47 0
Maximum QRS complex increase from baseline (ms) Change≥25% and baseline≥100 ms 76 0 48 0
Change≥50% and baseline<100 ms 76 0 48 0
N, number of patients who had at least one pair of time-matched baseline and postbaseline ECG data; n, number of patients in each category.
Table 4 Estimated effect of palbociclib on QTc at steady-state Cmax following repeated administration of 125mg palbociclib once daily
Mean drug-induced change in QTc (90% confidence interval)
Cmax (ng/ml) QTcS (ms) QTcF (ms) QTcB (ms)
Mean 116.6 4.04 (1.41–6.67) 4.14 (1.48–6.81) 3.17 (0.458–5.88)
Median 117.0 4.05 (1.41–6.69) 4.16 (1.48–6.83) 3.18 (0.460–5.90)
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mean maximum QTcF or QTcS of Z 500 ms or a
maximum increase from baseline of Z 60 ms during the
entire study period, which are the commonly used
thresholds for drug interruption or dose modification in a
given individual. Collectively, these results clearly indi-
cate a lack of a clinically relevant effect of palbociclib on
QTc when added to letrozole.
Further evidence of the lack of QT prolongation effect of
palbociclib was demonstrated by the exposure–response
(concentration-QTc) modeling. The linear mixed-effects
analysis was adequate to describe the relationship
between palbociclib concentrations and QTc or RR
interval. Incorporating nominal time as a factor variable
on the intercept in the model removes the potential
effect of the circadian rhythm on the QT interval. Such
models with time as a factor variable provide similar
accuracy of the slope estimates compared with complex
biological models with circadian functions, which require
more extensive ECG sampling for a precise estimation of
the model parameters [18]. The results from this analysis
showed that palbociclib did not appear to have a
concentration-dependent effect on the heart rate and the
predicted upper bound of the one-sided 95% CI for the
increase in QTc at the mean or median maximal steady-
state palbociclib concentrations at the therapeutic dose
was less than 10 ms. Taken together, these findings
indicate the lack of a clinically relevant effect of palbo-
ciclib on QTc.
The incidence of breast cancer increases with age and
hormone receptor-positive disease is more common in
postmenopausal women (median age in PALOMA-2,
62 years) [19]. Increasing age is associated with an
increase in cardiac risk factors and older patients are more
likely to be receiving concomitant medications that may
have an effect on the QTc [19–21]. When considering
treatment options for these patients, it is important to
consider medications that could impact QTc. Among the
CDK4/6 inhibitors currently approved for treatment, it
has been shown that ribociclib prolongs the QT interval
in a concentration-dependent manner [22]. Following the
administration of ribociclib at the recommended ther-
apeutic dose (600 mg once daily), the estimated mean
increase in QTc at the mean steady-state Cmax was
22.9 ms (90% CI: 21.6–24.1). As a result, the use of
ribociclib should be avoided in patients who already have
or who are at a significant risk of developing QTc pro-
longation and with drugs known to prolong QTc [22].
Palbociclib did not pose a clinical risk for QT prolonga-
tion at the recommended therapeutic dosing regimen,
supporting the current prescribing information with no
contraindications on concurrent cardiovascular disease
and no requirement for routine ECG monitoring. These
data suggest that QTc changes are not a class-effect of
CDK4/6 inhibitors, but rather molecule specific.
One limitation of the current study is the lack of higher
doses to achieve supratherapeutic concentrations in the
patient population. As discussed, dose-limiting toxicity
profiles associated with many oncology drugs preclude
the administration of doses higher than the maximum
tolerated dose (for palbociclib, 125 mg once daily 3 weeks
on, 1 week off) in cancer patients. However, previous
exposure–response analysis carried out using data from
early clinical trials included doses up to 225 mg once daily
administered in a 2 weeks on 1 week off schedule, which
provides sufficient coverage to assess the effect of pal-
bociclib at supratherapeutic concentrations [14]. This
earlier analysis also showed that the upper bound of the
one-sided 95% CI for the increase in QTcS did not
exceed 10ms.
Another limitation of the study is the lack of a positive
control (e.g. moxifloxacin), which is generally included in
TQT studies to establish the sensitivity of an assay to
detect the threshold of QTc changes of regulatory concern.
However, in a double-blinded, randomized phase 3 study,
it was not feasible to administer a positive control in a cross-
over design to patients. Similar study designs without a
positive control have been implemented in various oncol-
ogy trials [23,24]. Moreover, the use of a positive control,
which is known to prolong the mean QTc interval, may not
be tolerated in patients with advanced cancer who are
already at an increased risk for cardiac-related conditions
because of their poor health and age [19–21]. Nevertheless,
it should be emphasized that the current analysis was based
on robust data collected in a randomized, double-blind
study with strictly controlled conditions and standardized
methods for ECG and PK data collection, which ascertains
the validity of the results.
It is known that women have 10–20 ms longer QTc than
men [25,26] and are at a higher risk for developing
proarrhythmias caused by drugs that further prolong the
QTc [27]. Although the current analysis included data
from only female patients, a previous exposure–response
analysis carried out using data from both male and female
patients indicated that sex had no effect on the palboci-
clib concentration–QTc relationship [14].
Conclusion
The analyses presented in this article collectively demon-
strate that palbociclib, when coadministered with letrozole,
does not prolong QTc to a clinically meaningful extent and
QTc prolongation is not a safety concern for palbociclib at
the recommended therapeutic dosing regimen.
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